Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2021-07-28
Target enrollment:
Participant gender:
Summary
The study is to evaluate the efficacy and safety of apatinib for adjuvant treatment of
High-risk metastasis of nasopharyngeal carcinoma after IMRT with concurrent
chemotherapy,including progression-free survival (PFS),evaluation of drug safety.,and overall
survival (OS),distant metastasisfree survival (DMFS),locoregional relapse-free survival
(LRRFS),and quality of life score (QoL).
Phase:
Phase 2
Details
Lead Sponsor:
Wei Jiang
Collaborators:
Guangxi Minzu Hospital Guangxi Naxishan Hospital People's Hospital of Baise People's Hospital of Laibin People's Hospital of Lingshan Wuzhou Red Cross Hospital